medical decision support medical decision support
Sign In

Hazard Score of Yamaguchi et al for Determining the Prognosis for a Patient with an Adenocarcinoma of the Lung

Purpose: To predict survival in a patient with an adenocarcinoma of the lung using the hazard score of Yamaguchi et al.

Description

Yamaguchi et al developed a hazard ratio based on 4 clinical and molecular factors that can predict survival in a patient with an adenocarcinoma of the lung. The authors are from the University of Sao Paulo, the Institute of Advances in Medicine (Sao Paulo), Duke University and the Veterans Affairs Medical Center in Durham.


Patient selection: adenocarcinoma of the lung

 

Parameters:

(1) clinical stage

(2) histologic type (using the Noguchi classification for adenocarcinomas)

(3) tumor cell staining for cyclo-oxygenase 2 (COX-2)

(4) tumor cell staining for matrix metalloproteinase 9 (MMP9)

 

Parameter

Finding

Points

clinical stage

Stage I

0

 

Stage II, III or IV

1

histologic type

papillary

1

 

other

0

COX-2 immunostaining

negative

0

 

any staining

1

MMP9 staining

percent of tumor cells staining

(percent)

 

hazard score =

= (0.955 * (points for stage)) - (1.12 * (points for histologic type)) - (1.23 * (points for COX-2 staining)) + (0.0884 * (percent staining with MMP9 from 0 to 100))

 

Hazard Ratio

Median Survival After Surgery

< -0.5

5 years

-0.5 to 1.0

2 years

> 1.0

9 months

 


To read more or access our algorithms and calculators, please log in or register.

Specialty

Objective

ICD-10